Compare · AHCO vs OPCH
AHCO vs OPCH
Side-by-side comparison of AdaptHealth Corp. (AHCO) and Option Care Health Inc. (OPCH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AHCO and OPCH operate in Medical/Nursing Services (Health Care), so they compete in similar markets.
- OPCH is the larger of the two at $3.15B, about 2.4x AHCO ($1.31B).
- Over the past year, AHCO is up 10.1% and OPCH is down 34.2% - AHCO leads by 44.3 points.
- OPCH has been more active in the news (13 items in the past 4 weeks vs 3 for AHCO).
- OPCH has more recent analyst coverage (15 ratings vs 12 for AHCO).
- Company
- AdaptHealth Corp.
- Option Care Health Inc.
- Price
- $9.71+0.67%
- $20.84+3.84%
- Market cap
- $1.31B
- $3.15B
- 1M return
- -14.10%
- +1.66%
- 1Y return
- +10.15%
- -34.20%
- Industry
- Medical/Nursing Services
- Medical/Nursing Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 3
- 13
- Recent ratings
- 12
- 15
AdaptHealth Corp.
AdaptHealth Corp., together with its subsidiaries, provides home healthcare equipment, medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; home medical equipment (HME) to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME medical devices and supplies on behalf of chronically ill patients with diabetes care, wound care, urological, ostomy, and nutritional supply needs. It serves beneficiaries of Medicare, Medicaid, and commercial payors. The company is headquartered in Plymouth Meeting, Pennsylvania.
Option Care Health Inc.
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides immunoglobulin infusion therapies for the treatment of immune deficiencies; anti-infective therapies and services; home infusion services to treat heart failures; and treatments for chronic inflammatory disorders, including Crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders; and immunoglobulin infusion therapies. It also offers infusion therapies for bleeding disorders; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications. In addition, the company offers therapies that women need to survive and thrive through high-risk pregnancies; treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy; and nursing services. The company is headquartered in Bannockburn, Illinois.
Latest AHCO
- Chief Commercial Officer Schuster Iii Russell E. sold $113,426 worth of shares (11,275 units at $10.06) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 136,538 units (SEC Form 4)
- Amendment: AdaptHealth Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Operating Officer Mcfadden Daniel Edward was granted 20,134 shares, increasing direct ownership by 24% to 103,376 units (SEC Form 4)
- SEC Form 10-Q filed by AdaptHealth Corp.
- AdaptHealth Corp. to Participate in Upcoming Investor Conferences
- AdaptHealth Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits
- AdaptHealth Corp. Announces First Quarter 2026 Results
- Amendment: Chief Technology Officer Prast Albert A. covered exercise/tax liability with 58,203 shares, decreasing direct ownership by 15% to 338,712 units (SEC Form 4)
- SEC Form DEF 14A filed by AdaptHealth Corp.
- AdaptHealth Corp. Announces First Quarter 2026 Earnings Release Date and Conference Call
Latest OPCH
- Goldman initiated coverage on Option Care Health with a new price target
- Option Care Health Appoints Robert Okunski as Vice President, Investor Relations
- Option Care Health Awarded TIME's World's Most Impactful Companies 2026 Ranking
- Director Bierbower Elizabeth D was granted 8,997 shares, increasing direct ownership by 38% to 32,871 units (SEC Form 4)
- Director Deckmann Natasha was granted 9,841 shares, increasing direct ownership by 44% to 32,002 units (SEC Form 4)
- Director Kraemer Harry M Jansen Jr was granted 21,076 shares, increasing direct ownership by 5% to 471,076 units (SEC Form 4)
- Director Pate R Carter was granted 8,997 shares, increasing direct ownership by 77% to 20,620 units (SEC Form 4)
- Director Sullivan Timothy P was granted 13,833 shares, increasing direct ownership by 19% to 87,216 units (SEC Form 4)
- Director Bodem Barbara W. was granted 8,997 shares, increasing direct ownership by 74% to 21,087 units (SEC Form 4)
- Director Wright Norman L. was granted 8,997 shares, increasing direct ownership by 58% to 24,498 units (SEC Form 4)